Clinical Trials - January 17, 2014
Interim results from a phase II all-oral combination study of Simeprevir and Samatasvir
Medivir announces that Idenix Pharmaceuticals today released interim data from the ongoing phase II HELIX-1 clinical trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A inhibitor, and simeprevir , a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir, and ribavirin. The combination regimen of the […]
Pharma Business - September 27, 2013
Medivir’s Simeprevir has been approved in Japan
Medivir today reports that that simeprevir has been approved for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. “The approval in Japan is a very important step in providing patients with new treatment options. It is the first approval based on the series of global filings that our partner initiated during 2013. […]